Genprex, Inc. (GNPX)
| Previous Close | 2.1200 |
| Open | 2.1700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.1000 - 2.3292 |
| 52 Week Range | 2.0900 - 42.4000 |
| Volume | |
| Avg. Volume | 88,740 |
| Market Cap | 4.222M |
| Beta (5Y Monthly) | -0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -22.5600 |
| Earnings Date | May 22, 2024 - May 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 165.00 |
PR NewswireGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 America
ZacksGenprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
- PR Newswire
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that through its collaboration agreement with a large network of integrated, community-based oncology practices, the Company has added multiple clinical trial sites for its Acclaim-3 clinical study of Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) in combination with Genentech's Tecentriq® (at
